Collaboration Between the Beckman Coulter and Saladax Biomedical for Antipsychotic Therapeutic Drug Monitoring (TDM) Test Kits

March 15, 2022, Beckman Coulter announced its collaboration with Saladax Biomedical. As part of this agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the rapid assay test kits used to analyze blood levels of the antipsychotic drugs such as Clozapine, Risperidone/Paliperidone, Olanzapine, Quetiapine, and Aripiprazole. These drugs help to treat Schizophrenia, Bipolar Disorder, and Psychotic Disorders. According to the National Institute of Mental Health (NIMH), the prevalence of schizophrenia and related psychotic disorders in the USA range between 0.25% and 0.64%. These rapid tests kits run on the Beckman Coulter'™s scalable AU clinical chemistry analyzers and provide the results in a shorter time frame which would help the physicians to manage and monitor treatments for inpatients and outpatients